GoodRx (GDRX) Stock Price, News & Analysis

Company Overview

GoodRx Holdings, Inc. operates a leading digital platform that helps consumers across the United States find and compare prescription drug prices at retail pharmacies. Through its website and mobile applications, the company aggregates real-time pricing data from pharmacies and pharmacy benefit managers to deliver coupons, discount cards, and pricing insights. This model enables individuals—whether uninsured, underinsured, or insured with high deductibles—to reduce out-of-pocket costs on a broad range of medications.

Beyond prescription savings, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual medical consultations for non-emergency conditions such as allergies, skin issues, and sexual health concerns. Patients can connect with licensed healthcare professionals online to obtain diagnoses, treatment plans, and e-prescriptions, streamlining access to care and the subsequent procurement of affordable medications. The company also introduced GoodRx Gold, a subscription plan that delivers deeper discounts and additional member benefits.

Founded in 2011 by Douglas Hirsch and Trevor Bezdek, GoodRx has evolved through strategic partnerships and acquisitions. Early collaborations with national pharmacies and pharmacy benefit managers established its pricing database, while acquisitions like HeyDoctor expanded its telehealth capabilities. The launch of RxSaver further broadened the company’s reach by offering additional savings tools to both consumers and pharmacy chains.

Headquartered in Santa Monica, California, GoodRx focuses exclusively on the U.S. market. Under the leadership of CEO Douglas Hirsch and a management team experienced in technology, healthcare, and consumer services, the company continues to refine its digital offerings. Emphasizing affordability and convenience, GoodRx aims to transform how patients access and pay for prescription medications and basic healthcare services.

Key Stats

• Today's Range: $4.68 to $5.05
• 50-Day Range: $3.74 to $5.07
• 52-Week Range: $3.68 to $9.26
• Volume: 2.82 million shs
• Average Volume: 1.43 million shs
• Market Capitalization: $1.70 billion
• P/E Ratio: 59.49
• Dividend Yield: N/A
• Price Target: $6.55
• Consensus Rating: Moderate Buy

GoodRx Stock Analysis - MarketRank™

GoodRx scored higher than 54% of companies evaluated by MarketBeat, and ranked 1474th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

GoodRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on 5 buy ratings, 5 hold ratings, and no sell ratings.

Amount of Analyst Coverage

GoodRx has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 38.46%

Earnings Growth

Earnings for GoodRx are expected to grow by 38.46% in the coming year, from $0.13 to $0.18 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of GoodRx is 59.49, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.58.

Price to Earnings Ratio vs. Sector

The P/E ratio of GoodRx is 59.49, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.40.

Price to Earnings Growth Ratio

GoodRx has a PEG Ratio of 2.25. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

GoodRx has a P/B Ratio of 2.52. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.48% of the float of GoodRx has been sold short.

Short Interest Ratio / Days to Cover

GoodRx has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in GoodRx has recently increased by 6.29%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

GoodRx does not currently pay a dividend.

Dividend Growth

GoodRx does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.48% of the float of GoodRx has been sold short.

Short Interest Ratio / Days to Cover

GoodRx has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in GoodRx has recently increased by 6.29%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 4 news articles for GoodRx this week, compared to 5 articles on an average week.

Search Interest

Only 4 people have searched for GDRX on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, GoodRx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $94,919.00 in company stock.

Percentage Held by Insiders

Only 4.53% of the stock of GoodRx is held by insiders.

Percentage Held by Institutions

63.77% of the stock of GoodRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

GDRX Stock Analysis - Frequently Asked Questions

How have GDRX shares performed this year?

GoodRx's stock was trading at $4.65 on January 1st, 2025. Since then, GDRX stock has increased by 2.3% and is now trading at $4.7590.

How were GoodRx's earnings last quarter?

GoodRx Holdings, Inc. (NASDAQ:GDRX) issued its quarterly earnings data on Wednesday, May, 7th. The company reported $0.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.05. GoodRx's revenue for the quarter was up 2.6% on a year-over-year basis.
Read the conference call transcript.

When did GoodRx IPO?

GoodRx (GDRX) raised $900 million in an initial public offering (IPO) on Wednesday, September 23rd 2020. The company issued 34,600,000 shares at $24.00-$28.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and Barclays acted as the underwriters for the IPO and BofA Securities, Citigroup, Credit Suisse, RBC Capital Markets, UBS Investment Bank, Cowen, Deutsche Bank Securities, Evercore ISI, Citizens Capital Markets, KKR, LionTree, Raymond James, SVB Leerink, Academy Securities, Loop Capital Markets, R. Seelaus and Ramirez were co-managers.

How do I buy shares of GoodRx?

Shares of GDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of GoodRx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that GoodRx investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

• Last Earnings: 5/07/2025
• Today: 7/03/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Business Services
• Current Symbol: NASDAQ:GDRX
• CIK: 1809519
• Web: www.goodrx.com
• Phone: 855-268-2822
• Fax: N/A
• Employees: 950
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $6.55
• High Stock Price Target: $10.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +37.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.64
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.08
• Trailing P/E Ratio: 59.49
• Forward P/E Ratio: 36.61
• P/E Growth: 2.25
• Net Income: $16.39 million
• Net Margins: 3.57%
• Pretax Margin: 6.00%
• Return on Equity: 7.85%
• Return on Assets: 3.91%

Debt

• Debt-to-Equity Ratio: 0.74
• Current Ratio: 5.23
• Quick Ratio: 5.23

Sales & Book Value

• Annual Sales: $792.32 million
• Price / Sales: 2.15
• Cash Flow: $0.30 per share
• Price / Cash Flow: 15.89
• Book Value: $1.89 per share
• Price / Book: 2.52

Miscellaneous

• Outstanding Shares: 357,170,000
• Free Float: 340,989,000
• Market Cap: $1.70 billion
• Optionable: Optionable
• Beta: 1.24